Daewoong Pharmaceutical Past Earnings Performance
Past criteria checks 5/6
Daewoong Pharmaceutical has been growing earnings at an average annual rate of 60.4%, while the Pharmaceuticals industry saw earnings growing at 8.3% annually. Revenues have been growing at an average rate of 5.5% per year. Daewoong Pharmaceutical's return on equity is 13.2%, and it has net margins of 8.9%.
Key information
60.4%
Earnings growth rate
59.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 11.3% |
| Revenue growth rate | 5.5% |
| Return on equity | 13.2% |
| Net Margin | 8.9% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Daewoong Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 1,375,329 | 121,739 | 383,418 | 171,573 |
| 30 Sep 23 | 1,341,290 | 46,381 | 378,474 | 173,689 |
| 30 Jun 23 | 1,332,284 | 51,305 | 382,722 | 172,737 |
| 31 Mar 23 | 1,304,151 | 44,030 | 375,154 | 170,379 |
| 31 Dec 22 | 1,280,092 | 42,240 | 368,342 | 163,602 |
| 30 Sep 22 | 1,255,325 | 82,107 | 353,493 | 147,550 |
| 30 Jun 22 | 1,214,081 | 72,576 | 336,475 | 137,991 |
| 31 Mar 22 | 1,181,714 | 61,231 | 326,622 | 132,725 |
| 31 Dec 21 | 1,152,976 | 24,506 | 317,559 | 127,269 |
| 30 Sep 21 | 1,117,201 | 11,539 | 307,310 | 126,287 |
| 30 Jun 21 | 1,103,387 | 2,971 | 299,168 | 125,983 |
| 31 Mar 21 | 1,067,635 | -11,030 | 294,321 | 122,936 |
| 31 Dec 20 | 1,055,424 | 12,753 | 302,954 | 115,218 |
| 30 Sep 20 | 1,075,831 | -1,657 | 307,612 | 115,679 |
| 30 Jun 20 | 1,068,433 | -2,480 | 321,931 | 111,557 |
| 31 Mar 20 | 1,107,158 | 16,828 | 322,501 | 107,536 |
| 31 Dec 19 | 1,113,426 | 22,006 | 311,748 | 109,441 |
| 30 Sep 19 | 1,098,180 | -8,021 | 300,878 | 109,633 |
| 30 Jun 19 | 1,086,724 | -6,314 | 279,069 | 110,241 |
| 31 Mar 19 | 1,055,675 | -12,079 | 266,121 | 110,137 |
| 31 Dec 18 | 1,031,427 | -15,152 | 255,892 | 112,961 |
| 30 Sep 18 | 995,896 | 19,610 | 245,052 | 112,661 |
| 30 Jun 18 | 990,152 | 25,296 | 246,327 | 114,741 |
| 31 Mar 18 | 973,800 | 31,077 | 244,366 | 114,720 |
| 31 Dec 17 | 960,307 | 31,581 | 246,833 | 107,939 |
| 30 Sep 17 | 959,672 | 39,318 | 238,630 | 108,184 |
| 30 Jun 17 | 927,950 | 34,453 | 234,693 | 104,439 |
| 31 Mar 17 | 898,632 | 27,433 | 234,233 | 101,974 |
| 31 Dec 16 | 883,920 | 26,970 | 229,623 | 103,691 |
| 30 Sep 16 | 862,689 | 19,704 | 240,559 | 91,898 |
| 30 Jun 16 | 869,026 | 26,021 | 235,219 | 73,045 |
| 31 Mar 16 | 857,252 | 34,413 | 223,333 | 51,712 |
| 31 Dec 15 | 839,686 | 42,930 | 215,954 | 31,068 |
| 30 Sep 15 | 812,337 | 44,657 | 205,139 | 17,129 |
| 30 Jun 15 | 778,975 | 28,576 | 201,929 | 15,271 |
| 31 Mar 15 | 758,475 | 30,555 | 197,536 | 17,819 |
| 31 Dec 14 | 735,889 | 31,544 | 193,043 | 18,743 |
| 30 Sep 14 | 734,716 | 31,176 | 189,697 | 20,823 |
| 30 Jun 14 | 714,185 | 56,700 | 184,260 | 20,873 |
| 31 Mar 14 | 690,275 | 58,808 | 185,059 | 20,249 |
| 31 Dec 13 | 682,508 | 58,400 | 190,100 | 21,170 |
| 30 Sep 13 | 639,940 | 60,137 | 190,704 | 20,662 |
| 30 Jun 13 | 644,237 | 46,738 | 196,428 | 20,166 |
Quality Earnings: A069620 has high quality earnings.
Growing Profit Margin: A069620's current net profit margins (8.9%) are higher than last year (3.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A069620 has become profitable over the past 5 years, growing earnings by 60.4% per year.
Accelerating Growth: A069620's earnings growth over the past year (188.2%) exceeds its 5-year average (60.4% per year).
Earnings vs Industry: A069620 earnings growth over the past year (188.2%) exceeded the Pharmaceuticals industry 36.1%.
Return on Equity
High ROE: A069620's Return on Equity (13.2%) is considered low.